alopecia

Posts

Global Alopecia Treatment Market

Global Alopecia Treatment Market

/in /by

Global Alopecia Treatment Market

The Alopecia Treatment market is expected to grow in the future due to a rising R&D activity to improve treatment options and accelerated regulatory approvals.

There are five major kinds of alopecia to be specific such as androgenic alopecia, alopecia areata, alopecia totalis, cicatricial alopecia, and telogen effluvium.

The rising prevalence of chronic diseases, such as acute stress disorder, Polycystic Ovary Disease (PCOD), hyperthyroidism, hypothyroidism, cancer, lupus, and hypopituitarism across the globe, is expected to augment the revenue growth over the forecast period.

Growth Drivers

  • Surge in Geriatric Population
  • Rise in Prevalence of Alopecia Conditions such as Androgenic Alopecia, Alopecia Areata, Alopecia Totalis, and Others
  • Increase in Prevalence of Chemotherapy-Induced Alopecia

Market Trends

  • Technological Advancements and the Development of Novel Therapeutic Drugs

Roadblocks

  • Lack of Reimbursement Policies
  • High Cost of Medications

Opportunities

  • Surge in Patient Awareness Regarding the Alopecia Totalis Disorder
  • Large Presence of Pharmaceutical Companies

Challenges

  • Side Effects, Reactions, and Allergies Caused by Alopecia Treatments

Competitive Landscape:

The global Alopecia Treatment market is witnessing a rise in competitiveness among the players. In terms of market share, the major players are currently dominating. However, some of the companies are increasing the market presence by securing new contracts and tapping new markets.

Some of the key players profiled in the report are Johnson & JohnsonServices, Inc. (United States), Sun Pharmaceutical Industries Ltd (India), Cipla Inc. (India), Lexington International LLC (United States), Merck & Co., Inc. (United States), Vita-Cos-Med Klett-Loch GmbH (Germany), Cirrus Hair Centers (United States), Transitions Hair Pty Ltd. (United States), Capillus (United States) and Follica, Inc. (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Alopecia Treatment market by 2025.

Considering Market by Drug, the sub-segment i.e. Minoxidil will boost the Alopecia Treatment market. Considering Market by Sales Channel, the sub-segment i.e. Prescriptions will boost the Alopecia Treatment market. Considering Market by End User, the sub-segment i.e. Hospitals will boost the Alopecia Treatment market.

Latest Market Insights:

In Mar 2020, Eli Lilly and Company and Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to baricitinib for the treatment of alopecia areata (AA), an autoimmune disorder that can cause unpredictable hair loss on the scalp, face and other areas of the body.

In June 2020, Follica, Inc. announced positive feedback from a meeting with the U.S. Food and Drug Administration (FDA) as the company prepares to advance its lead program into Phase 3 development following a successful safety and efficacy optimization study for the treatment of hair loss in male androgenetic alopecia announced in December 2019., and In Oct 2020, Histogen Inc. announced the completion of patient dosing in its Phase 1b/2a clinical trial of HST-001, designed to assess the safety, tolerability, and indicators of efficacy of HST-001 for the treatment of androgenic alopecia in men.

Global Alopecia Treatment Market

Source

Recent Posts

Global Alopecia Treatment Market

Global Alopecia Treatment Market

/in /by

Global Alopecia Treatment Market

The Alopecia Treatment market is expected to grow in the future due to a rising R&D activity to improve treatment options and accelerated regulatory approvals.

There are five major kinds of alopecia to be specific such as androgenic alopecia, alopecia areata, alopecia totalis, cicatricial alopecia, and telogen effluvium.

The rising prevalence of chronic diseases, such as acute stress disorder, Polycystic Ovary Disease (PCOD), hyperthyroidism, hypothyroidism, cancer, lupus, and hypopituitarism across the globe, is expected to augment the revenue growth over the forecast period.

Growth Drivers

  • Surge in Geriatric Population
  • Rise in Prevalence of Alopecia Conditions such as Androgenic Alopecia, Alopecia Areata, Alopecia Totalis, and Others
  • Increase in Prevalence of Chemotherapy-Induced Alopecia

Market Trends

  • Technological Advancements and the Development of Novel Therapeutic Drugs

Roadblocks

  • Lack of Reimbursement Policies
  • High Cost of Medications

Opportunities

  • Surge in Patient Awareness Regarding the Alopecia Totalis Disorder
  • Large Presence of Pharmaceutical Companies

Challenges

  • Side Effects, Reactions, and Allergies Caused by Alopecia Treatments

Competitive Landscape:

The global Alopecia Treatment market is witnessing a rise in competitiveness among the players. In terms of market share, the major players are currently dominating. However, some of the companies are increasing the market presence by securing new contracts and tapping new markets.

Some of the key players profiled in the report are Johnson & JohnsonServices, Inc. (United States), Sun Pharmaceutical Industries Ltd (India), Cipla Inc. (India), Lexington International LLC (United States), Merck & Co., Inc. (United States), Vita-Cos-Med Klett-Loch GmbH (Germany), Cirrus Hair Centers (United States), Transitions Hair Pty Ltd. (United States), Capillus (United States) and Follica, Inc. (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Alopecia Treatment market by 2025.

Considering Market by Drug, the sub-segment i.e. Minoxidil will boost the Alopecia Treatment market. Considering Market by Sales Channel, the sub-segment i.e. Prescriptions will boost the Alopecia Treatment market. Considering Market by End User, the sub-segment i.e. Hospitals will boost the Alopecia Treatment market.

Latest Market Insights:

In Mar 2020, Eli Lilly and Company and Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to baricitinib for the treatment of alopecia areata (AA), an autoimmune disorder that can cause unpredictable hair loss on the scalp, face and other areas of the body.

In June 2020, Follica, Inc. announced positive feedback from a meeting with the U.S. Food and Drug Administration (FDA) as the company prepares to advance its lead program into Phase 3 development following a successful safety and efficacy optimization study for the treatment of hair loss in male androgenetic alopecia announced in December 2019., and In Oct 2020, Histogen Inc. announced the completion of patient dosing in its Phase 1b/2a clinical trial of HST-001, designed to assess the safety, tolerability, and indicators of efficacy of HST-001 for the treatment of androgenic alopecia in men.

Global Alopecia Treatment Market

Source

Recent Posts

Global Alopecia Treatment Market

Global Alopecia Treatment Market

/in /by

Global Alopecia Treatment Market – Industry Trends and Forecast to 2027

Market Analysis and Insights: Global Alopecia Treatment (Hair Loss) Market

The alopecia treatment (hair loss) market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.0% in the forecast period of 2020 to 2027 and is expected to reach USD 5,461.35 million by 2027. The rising prevalence of alopecia (hair loss) globally and extensive research & development activity in alopecia treatment (hair loss) are the major drivers which propelled the demand of the alopecia treatment (hair loss) market in the forecast period.

Alopecia treatment comprises features such as increasing need for an effective treatment for alopecia (hair loss) which will impact in launching new products by the manufacturers into the alopecia treatment (hair loss) market which enhance its demand as well as rising pharmaceutical industries initiatives leads to the alopecia treatment (hair loss) market growth.

Currently, various research & clinical studies are going on which is expected to create a competitive advantage for manufacturers to develop new and innovative alopecia treatment (hair loss) market. Moreover, these clinical programmes are also expected to provide various other opportunities in the alopecia treatment (hair loss) market. However, lack of awareness in rural countries and high cost of treatment is expected to restraint the alopecia treatment (hair loss) market growth in the forecast period.

The alopecia treatment (hair loss) market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the alopecia treatment (hair loss) market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Alopecia Treatment (Hair Loss) Market Scope and Market Size

The alopecia treatment (hair loss) market is segmented on the basis of disease type, treatment, gender, form, end-user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of disease type, the alopecia treatment (hair loss) market is segmented into non-cicatricial alopecia, cicatricial alopecia, traction alopecia and others. In 2020, the non‒cicatricial alopecia segment is dominating the alopecia treatment (hair loss) market as non‒cicatricial alopecia has the highest prevalence rate across the globe and affects a majority of the population.
  • On the basis of treatment, the alopecia treatment (hair loss) market is segmented into localized therapies, systemic therapies, medical devices and herbal treatment. In 2020, localized therapies segment is dominating the alopecia treatment (hair loss) market due to first-line treatment to reduce the symptoms of alopecia and increase the hair growth.
  • On the basis of gender, the alopecia treatment (hair loss) market is segmented into male and female. In 2020, the male segment is dominating the alopecia treatment (hair loss) market due to the large number of male population affected by the androgenetic alopecia.
  • On the basis of form, the alopecia treatment (hair loss) market is segmented into oral, topical and parenteral. In 2020, the topical segment is dominating the alopecia treatment (hair loss) market as a topical form offers patients with huge compliance and high satisfaction.
  • On the basis of end-user, the alopecia treatment (hair loss) market is segmented into hospitals, home healthcare and dermatology centres. In 2020, dermatology centres segment is dominating the alopecia treatment (hair loss) market because alopecia is a dermatology related disorder and required innovative treatment solutions for hair loss.
  • On the basis of the distribution channel, the alopecia treatment (hair loss) market is segmented into direct tender, retail sales and pharmacies. In 2020, pharmacies segment is dominating the alopecia treatment (hair loss) market because, for the treatment of alopecia or hair loss, majority of the formulation are available on OTC, which do not require a prescription and also offers patients with instant gratification.

Global Alopecia Treatment (Hair Loss) Market Country Level Analysis

Global alopecia treatment (hair loss) market is analyzed and market size information is provided by country, disease type, treatment, gender, form, end-user and distribution channel as referenced above.

The countries covered in the alopecia treatment (hair loss) market report are the U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and rest of the Middle East and Africa.

Non‒cicatricial alopecia segment in North America region is expected to grow with the highest growth rate in the forecast period of 2020 to 2027 since it is the most common form of alopecia and people with alopecia aerate affects approximately 6.8 million people in the U.S. Japan is leading the growth of the Asia-Pacific alopecia treatment (hair loss) market and non‒cicatricial alopecia segment is dominating in the region due to rise in prevalence of alopecia and rising usage of hair care therapies for the treatment. The non‒cicatricial alopecia segment in Germany is dominating the European alopecia treatment (hair loss) market owing to the increasing demand for effective treatment.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.

Continuous Increasing Awareness for Alopecia Treatment (Hair Loss) is boosting the Alopecia Treatment (Hair Loss) Market Growth

Alopecia treatment (hair loss) market also provides you with detailed market analysis for every country growth in alopecia treatment (hair loss) industry with alopecia treatment (hair loss) drugs sales, the impact of advancement in the alopecia treatment (hair loss) technology and changes in regulatory scenarios with their support for the alopecia treatment (hair loss) market. The data is available for the historic period 2010 to 2018.

Competitive Landscape and Alopecia Treatment (Hair Loss) Market Share Analysis

Alopecia treatment (hair loss) market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to alopecia treatment (hair loss) market.

The major companies which are dealing in the global alopecia treatment (hair loss) market report are Alès Groupe, Gerolymatos International SA, iGrow Laser, Lexington Intl., LLC., Curallux, LLC., Follicum AB, HCell Inc., Freedom Laser Therapy, Inc., Taisho Pharmaceutical Holdings Co., Ltd., Vita-Cos-Med Klett-Loch GmbH, Vitabiotics Ltd., WOCKHARDT, Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceuticals Industries Ltd.), Pfizer Inc., Par Pharmaceutical (a subsidiary of Endo International plc), GlaxoSmithKline plc, Dr. Reddy’s Laboratories Ltd., Abbott, Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila), Johnson & Johnson Services, Inc., Cipla Inc., Sun Pharmaceutical Industries Ltd., Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.), Aurobindo Pharma, Perrigo Company plc, Viviscal Limited (a subsidiary of Church & Dwight Co., Inc.), Dr. Kurt Wolff GmbH & Co. KG, Nanogen, Labo International S.r.l., Watermans, WON TECH Co., Ltd., PureTech among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launches and agreements are also initiated by the companies’ worldwide which are also accelerating the alopecia treatment (hair loss) market.

For instance,

  • In March 2018, Johnson & Johnson Services, Inc. teamed up with JW Pharmaceutical to enhance the sales of its product which is Rogaine, a hair loss treatment containing minoxidil. JW Pharmaceutical has signed an exclusive distributorship agreement with J&J in November 2017. Rogaine is FDA approved hair loss treatment and is considered a top-selling hair loss treatment. This initiative allowed the company to earn more product sales which has boosted the company’s overall revenue.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the alopecia treatment (hair loss) market which also provides the benefit for the organization to improve their offering for alopecia treatment (hair loss).

Customization Available: Global Alopecia Treatment (Hair Loss) Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Global Alopecia Treatment Market – Industry Trends and Forecast to 2027

Source

Recent Posts

Phase 2a trial evaluating CTP-543

Evaluating CTP-543 for Alopecia Areata

/in /by

Concert Pharmaceuticals Initiates THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced it has initiated THRIVE-AA1, the first Phase 3 clinical trial to evaluate the efficacy and safety of CTP-543, an oral Janus kinase inhibitor, in adult patients with moderate to severe alopecia areata. The Company expects to report topline results from THRIVE-AA1 in 2022. A second Phase 3 trial, THRIVE-AA2, is expected to begin in the first half of 2021.

“Based on the results from our Phase 2 program, we believe CTP-543 has the potential to offer patients a best-in-class treatment for moderate to severe alopecia areata,” said James V. Cassella, Ph.D., Chief Development Officer, Concert Pharmaceuticals. “We are fully committed to advancing CTP-543 with its Breakthrough Therapy designation in order to make a meaningful difference in the lives of individuals impacted by alopecia areata.”

The initiation of THRIVE-AA1 follows an end-of-phase 2 meeting where Concert discussed key aspects of its Phase 3 program and registration strategy with the U.S. Food and Drug Administration (FDA). The end-of-phase 2 meetings with the FDA was held following positive results from a dose-ranging Phase 2 trial of CTP-543 in patients with moderate to severe alopecia areata. Under current timelines, the Company believes that positive results from two Phase 3 trials could serve as the basis for submitting a New Drug Application in early 2023 for CTP-543 for the treatment of moderate to severe alopecia areata in adult patients.

“There are millions of people around the world affected by and living with alopecia areata,” said Andy Bryant, Acting Chief Executive Officer of the National Alopecia Areata Foundation. “We’re encouraged by CTP-543’s potential to be one of the first FDA-approved medicines to treat alopecia areata.”

About the THRIVE-AA1 Study

THRIVE-AA1 (NCT04518995) is a randomized, double-blind, placebo-controlled clinical trial in adult patients with moderate to severe alopecia areata at sites in the U.S., Canada and Europe evaluating the regrowth of scalp hair after 24 weeks of dosing using the Severity of Alopecia Tool (SALT). Key aspects of THRIVE-AA1 include:

  • Patient characteristics: adults age 18-65 years with ≥ 50% hair loss are eligible for the study;
  • Expected enrollment size: approximately 700 patients;
  • Dosing: 8 mg twice-daily or 12 mg twice-daily of CTP-543 or placebo for 24 weeks; and
  • Primary endpoint: Percent of patients achieving a SALT score ≤ 20 at Week 24.

For more information about the THRIVE-AA1 study, please visit https://clinicaltrials.gov/ct2/show/NCT04518995.

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted CTP-543 Breakthrough Therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 700,000 Americans at any given time1.

The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. The onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017.

The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development. Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report.

Concert Pharmaceuticals Initiates THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

Source

Recent Posts

CTP-543 Phase 3 Trials in Alopecia Areata

CTP-543 Alopecia Areata

/in /by

Concert Pharmaceuticals Announces CTP-543 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2020 EADV Virtual Congress

Concert Pharmaceuticals today announced that it will present clinical data on CTP-543 for the treatment of alopecia areata as a late-breaker oral presentation at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress. The meeting will be held virtually October 29-31, 2020.

The oral presentation will highlight new data from an ongoing open-label extension study evaluating long-term safety and treatment effects of CTP-543 in patients with moderate to severe alopecia areata.

The details of the presentation are as follows:

  • Title: Initial Results from a Long-Term, Open-Label Extension Study with CTP-543, an Oral Janus Kinase Inhibitor, in Patients with Moderate to Severe Alopecia Areata
  • Date and Time: Thursday, October 29, 2020, 3:00 – 3:15 pm Central European Time
  • Session: D1T03.3C: Late-Breaking News Session
  • Location: EADV Virtual Meeting. Registration is required to participate: https://eadvvirtualcongress.org/registration/

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The U.S. Food and Drug Administration (FDA) has granted CTP-543 Breakthrough Therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata.

The Company expects to begin Phase 3 evaluation of CTP-543 in the fourth quarter of 2020. Additional information on the upcoming trial is available on www.clinicaltrials.gov.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 700,000 Americans at any given time1.

The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017. The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development.

Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report. Additional information on the PFDDI is available online.

About Concert

Concert Pharmaceuticals is a clinical-stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs.

The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders.

For more information please visit www.concertpharma.com

1 Benigno M. Clinical, Cosmetic and Investigational Dermatology 2020

Concert Pharmaceuticals Announces CTP-543 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2020 EADV Virtual Congress

Source

Previous Post

Positive CTP-543 Results from Phase 2 Alopecia Areata Trial

CTP-543 for the Treatment of Alopecia Areata

/in /by

Concert Pharmaceuticals Receives FDA Breakthrough Therapy Designation for CTP-543 for the Treatment of Alopecia Areata

Concert Pharmaceuticals, Inc today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for the Company’s oral Janus kinase inhibitor, CTP-543, for the treatment of adult patients with moderate-to-severe alopecia areata.

There are currently no drugs approved by the FDA for the treatment of alopecia areata, an autoimmune disorder in which the immune system attacks hair follicles, resulting in patchy or complete hair loss.

FDA Breakthrough Therapy Designation is intended to expedite the development and review of medicines aimed at treating a serious or life-threatening disease where there is preliminary clinical evidence that the investigational therapy may offer a substantial improvement over existing therapies.

“We are pleased that the FDA has recognized the therapeutic potential of CTP-543 as a new treatment in development for alopecia areata,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “Our goal is to bring this potential new therapy to patients as quickly as possible. We look forward to working closely with the FDA to expedite the development of CTP-543.”

FDA Breakthrough Therapy Designation for CTP-543 is supported by positive data from a Phase 2 clinical trial in patients with moderate-to-severe alopecia areata.

In September 2019, Concert reported that patients treated with either 8 mg twice-daily or 12 mg twice-daily of CTP-543 met the primary efficacy endpoint with statistically significant differences (p <0.001) relative to placebo in the percentage of patients achieving a ≥ 50% relative change from baseline at 24 weeks as measured by Severity of Alopecia Tool (SALT).

The 8 mg twice daily and 12 mg twice-daily groups were also significantly different from placebo in the number of patients achieving a SALT score of 20 or less at 24 weeks, which is the primary efficacy endpoint that Concert intends to utilize in its pivotal registration studies. Treatment with CTP-543 was generally well-tolerated, with one serious adverse event reported in the 12 mg dose group where the patient was able to complete the trial after a brief dose interruption.

As the next step in the CTP-543 clinical program, Concert intends to initiate its Phase 3 clinical program in the fourth quarter of 2020.

CTP-543 has also received Fast Track designation in the U.S. for the treatment of alopecia areata.

Additional information about the CTP-543 Phase 2 results is available in the Scientific Presentations section of the Company’s website.

About the Phase 2 Trial Design of CTP-543 in Alopecia Areata

The Phase 2 trial was a double-blind, randomized, placebo-controlled, sequential dose trial to evaluate the safety and efficacy of CTP-543 in adult patients with moderate-to-severe alopecia areata.

A total of 149 patients were randomized to receive one of three doses of CTP-543 (4 mg, 8 mg or 12 mg) or placebo, administered twice-daily. The primary outcome measure utilized the SALT score after 24 weeks of dosing. The average baseline SALT score across all patients was approximately 88%, where 0% is no scalp hair loss and 100% represents total scalp hair loss.

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted Fast Track designation for CTP-543 for the treatment of alopecia areata. The Company intends to advance CTP-543 into Phase 3 evaluation in the fourth quarter of 2020.

c Alopecia areata may affect approximately 700,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. The onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017.

The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development. Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report.

Concert Pharmaceuticals Receives FDA Breakthrough Therapy Designation for CTP-543 for the Treatment of Alopecia Areata

Source

Recent Posts

Trial of HST 001 for Androgenic Alopecia

Trial of HST 001 for Androgenic Alopecia

/in /by

Histogen Announces First Patient Dosed in Phase 1b/2a Trial of HST 001 for Androgenic Alopecia

Histogen Inc, a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the enrollment of the first patient in its Phase 1b/2a clinical trial of HST 001, the Company’s lead therapeutic candidate for the treatment of androgenic alopecia in men.

This blinded, randomized, placebo-controlled, single-site study will enrol 36 subjects with male pattern hair loss using a 2:1 randomization HST 001 to placebo. It is designed to assess the safety and tolerability of HST 001, as well as indicators of efficacy including non-vellus hair count, total hair count, and hair thickness density as measured by Canfield macrophotography.

“The initiation of this clinical trial is a critical milestone for Histogen following the completion of our merger and listing on the Nasdaq Capital Market last week,” said Richard Pascoe, Chief Executive Officer of Histogen. “HST 001 is a potentially transformative approach to treating androgenic alopecia given that existing therapies focus on reducing hair loss, while HST 001 has the potential to stimulate new long-lasting hair growth.”

Building on prior clinical experience with HST 001, the Phase 1b/2a study will be the first company-sponsored trial to include a third dosing time point, with dosing taking place at week 0, week 6 and week 12.

At each treatment timepoint, subjects will receive 20 injections focused on temporal recession and vertex scalp areas, the most common regions of hair loss in men with androgenic alopecia.

Top-line data is anticipated to be available in the fourth quarter of 2020.

About HST 001

HST 001, or Hair Stimulating Complex (HSC), is intended to be a physician-administered therapeutic for hair loss. HSC is anticipated to be a relatively safe, minimally invasive treatment that promotes new hair growth where existing treatments only reduce hair loss.

HSC is manufactured to enrich for growth factors including KGF, VEGF, and follistatin, which are involved in signalling stem cells in the body and have been shown to be important in hair formation and the stimulation of resting hair follicles.

About Histogen

Histogen is a regenerative medicine company developing patented technologies that replace and regenerates tissues in the body. The company’s innovative technology platform utilizes cell-conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells, developing therapeutic products that address underserved, multi-billion US dollar global markets. For more information, please visit www.histogen.com.

Histogen Announces First Patient Dosed in Phase 1b/2a Trial of HST 001 for Androgenic Alopecia

Source

Previous Posts

Global Hair Transplant System Market Report

Global Hair Transplant Services Market

/in /by

Global Hair Transplant Services Market

Global Hair Transplant Services Market is accounted for xx USD million in 2019 and is expected to reach xx USD million by 2026 growing at a CAGR of xx% during the forecast period. The report offers in-depth insights, revenue details, and other vital information regarding the global Hair Transplant Services market and the various trends, drivers, restraints, opportunities, and threats in the target market till 2026.

Hair Transplant Services Market report covers size, share and forecast (value and volume) by regions, top players, product types and applications, with historical data along with forecast from 2019 to 2026; The report covers an in depth description, competitive scenario, wide product portfolio of key vendors and business strategy adopted by competitors along with their SWOT analysis, revenue, sales and Porter’s Five Forces Analysis.

By geography, this market has been segregated into five regions with revenue and growth rate of Hair Transplant Services from 2013 to 2026,

• North America  (U.S., Canada, Mexico)
• Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS)
• Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)
• Latin America (Brazil, Rest of L.A.)
• Middle East And Africa(Turkey, GCC, Rest of Middle East)

The major players operating into Hair Transplant Services Market include:

Bernstein Medical
Bosley
Medicamat
Hair Transplants of Florida
Cole Instruments
Limmer Hair Transplant Center
getFUE Hair Clinics
Hair Transplant Center
The Hairline Clinic
Capillus
LaserCap
Solta Medical
PhotoMedex

This report segments the Global Hair Transplant Services Market as follows:

Global Hair Transplant Services Market: Type Segment Analysis
Follicular Unit Transplantation (FUT)
Follicular Unit Extraction (FUE)
Scalp Reduction

Global Hair Transplant Services Market: Application Segment Analysis

Hospitals
Specialized Clinics
Ambulatory Surgical Centers

There are 13 chapters to put on view for Hair Transplant Services Market:

Chapter 1: Market Overview, Drivers, Restraints and Opportunities, Segmentation overview
Chapter 2: Market competition by Manufacturers
Chapter 3: Production by Regions
Chapter 4: Consumption by Regions
Chapter 5: Production, By Types, Revenue and Market share by Types
Chapter 6: Consumption, By Applications, Market share (%) and Growth Rate by Applications
Chapter 7: Complete profiling and analysis of Manufacturers
Chapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expenses
Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers
Chapter 10: Marketing Strategy Analysis, Distributors/Traders
Chapter 11: Market Effect Factors Analysis
Chapter 12: Market Forecast
Chapter 13: Hair Transplant Services Research Findings and Conclusion, Appendix, methodology and data source

Data type include capacity, production, market share, price, revenue, cost, gross, gross margin, growth rate, consumption, import, export have been determined using secondary sources and verified primary sources. Industry chain, manufacturing process, cost structure, marketing channel are also analyzed in this report.

Industry Chain Analysis

Raw Material and Suppliers
Equipment and Suppliers
Manufacturing Process
Manufacturing Cost Structure
Manufacturing Plants Distribution Analysis

Global Hair Transplant Services Market

Source

Previous Posts

Alopecia Treatment Market

Global Androgenic Alopecia Drug Market Insights

/in /by

Global Androgenic Alopecia Drug Market Insights, Forecast to 2025

In 2017, the global Androgenic Alopecia Drug market size was  million US$ and is forecast to  million US in 2025, growing at a CAGR of  from 2018. The objectives of this study are to define, segment, and project the size of the Androgenic Alopecia Drug market based on company, product type, application and key regions.

This report studies the global market size of Androgenic Alopecia Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Androgenic Alopecia Drug in these regions.

This research report categorizes the global Androgenic Alopecia Drug market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter’s Five Forces Analysis.

The various contributors involved in the value chain of Androgenic Alopecia Drug include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in the Androgenic Alopecia Drug include
Allergan, Inc.
Histogen, Inc.
R-Tech Ueno, Ltd.
Hygeia Therapeutics, Inc.
SWITCH Biotech LLC
Polichem S.A.
Kasiak Research Pvt. Ltd.

Market Size Split by Type
RK-023
Refagro
RCH-01
SM-04554
HYG-440
Others

Market Size Split by Application
Clinic
Hospital
Home Use

Market size split by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Androgenic Alopecia Drug market size (value & volume) by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025.
To understand the structure of Androgenic Alopecia Drug market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Androgenic Alopecia Drug manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Androgenic Alopecia Drug with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Androgenic Alopecia Drug submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Androgenic Alopecia Drug are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Androgenic Alopecia Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Global Androgenic Alopecia Drug Market Insights, Forecast to 2025

Source

Previous Posts

Alopecia Treatment Market Insights

Global Androgenic Alopecia Drug Market Report 2019

/in /by

Global Androgenic Alopecia Drug Market Report 2019

With the slowdown in world economic growth, the Androgenic Alopecia Drug industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Androgenic Alopecia Drug market size to maintain the average annual growth rate of XXX from XXX million $ in 2014 to XXX million $ in 2018.

Research analysts believe that in the next few years, Androgenic Alopecia Drug market size will be further expanded, we expect that by 2023, The market size of the Androgenic Alopecia Drug will reach XXX million $.

This Report covers the manufacturers’ data, including: shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better.

This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume and value, as well as price data.

Besides, the report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.

Manufacturer Detail
Allergan, Inc.
Histogen, Inc.
R-Tech Ueno, Ltd.
Hygeia Therapeutics, Inc.
SWITCH Biotech LLC
Polichem S.A.
Kasiak Research Pvt. Ltd.

Region Segmentation
North America Country (United States, Canada)
South America
Asia Country (China, Japan, India, Korea)
Europe Country (Germany, UK, France, Italy)
Other Country (Middle East, Africa, GCC)

Product Type Segmentation
RK-023
Refagro
RCH-01
SM-04554
HYG-440

Industry Segmentation
Clinic
Hospital
Home Use

Channel (Direct Sales, Distributor) Segmentation

Trend (2018-2023)

Product Type Detail

Downstream Consumer

Cost Structure

Conclusion

Global Androgenic Alopecia Drug Market Report 2019

Source

Previous Posts

Positive CTP-543 Results from Phase 2 Alopecia Areata Trial

CTP-543 Phase 2 Alopecia Areata

/in /by

Concert Pharmaceuticals Announces CTP-543 Phase 2 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2019 EADV Congress

-Concert Pharmaceuticals today announced that it will present results from its recently completed Phase 2 trial of CTP-543 in patients with moderate-to-severe alopecia areata. These data will be presented in the late breaking news session at the European Academy of Dermatology and Venereology (EADV) Annual Congress to be held October 9– 13, 2019 in Madrid, Spain.

The details of the presentation are as follows:

Title: CTP-543, an oral JAK inhibitor, achieves primary endpoint in Phase 2 randomized, placebo-controlled, dose ranging trial in patients with moderate-to-severe alopecia areata
Date and Time: Saturday, October 12, 2019 at 9:15 – 9:30 GMT
Session: Late-Breaking News Session
Room: Hall 10 Dali

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2 for the potential treatment of alopecia areata. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CTP-543 for the treatment of alopecia areata.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 650,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp.

Onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017. The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development.

Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report. Additional information on the PFDDI is available online.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs.

The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

1 Fricke M. Epidemiology and Burden of alopecia areata: a systemic review. Clinical, Cosmetic and Investigational Dermatology. 2015; Vol 8. 397-403.

Concert Pharmaceuticals Announces CTP-543 Phase 2 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2019 EADV Congress

Source

Previous Posts